DITA Content Management for Regulatory Compliance in Life Sciences
MadCap IXIA CCMS operates in an environment that supports FDA 21 CFR Part 11 and other regulatory standards, with map-level approval workflows, complete audit trails, and DITA component-based content reuse. Life sciences teams produce consistent, auditable documentation, from Instructions for Use and regulatory submissions to clinical protocols, with structured authoring that eliminates dangerous inconsistencies across products and markets.
Regulated Content Authoring for Life Sciences, Healthcare, and Pharmaceutical is the controlled creation, review, translation, and submission of clinical documentation, instructions for use, package inserts, and standard operating procedures under FDA (GxP), EMA, and MDR/IVDR regulations. Organizations require complete traceability from source content through approved output, with electronic signatures and audit-ready change history. MadCap IXIA CCMS supports these obligations through DITA-based component content management with full version control, branching workflows, and configurable reviews and approvals aligned with 21 CFR Part 11 expectations.
Purpose-Built Capabilities for Life Sciences Documentation
Regulatory Compliance
Operate in a regulation-friendly environment with electronic records, audit trails, and map-level approval workflows. Configurable review processes support compliant status transitions aligned with regulatory expectations.
Component-Based IFU Authoring
Author Instructions for Use with DITA component reuse so safety warnings, drug interactions, and contraindications are written once and managed through shared libraries, cascading only to the documents that require them.
Multilingual Regulatory Publishing
Publish regulated content in dozens of languages with Unified Localization. Topic-based translation workflows and TMS-agnostic automation send only changed components to translators, and integrates with MadTranslations for streamlined delivery. Fast multilingual turnaround supports faster global market launches.
Configurable Approval Workflows
Enforce the review and approval processes required by FDA and EMA standards. The Collaborative Review and Approval features track assigned reviewers and approvers through every stage of the documentation lifecycle. Enforced double authentication on approvals ensures the sign-off process is fully handled within IXIA CCMS.
eIFU Publishing for EU MDR/IVDR
Supports EU MDR/IVDR electronic IFU workflows with multi-format, multi-language publishing from a single DITA source.
AI-Assisted Regulatory Authoring
Accelerate documentation drafts with AI Positron Assistant while maintaining terminology consistency across IFUs, regulatory submissions, and clinical protocols. Document-level templates and baselined IFU templates let teams quickly create compliant content from proven starting points.
Role-Based Access Controls
Enforce content security with role-based permissions that restrict access to sensitive regulatory documentation. Audit trails track every content change, providing full traceability for regulatory audits. Purpose-built audit reports answer medical device audit requests directly, and redline capabilities highlight content changes since the last submission.
Enterprise Content Repository
Manage thousands of regulated topics in the TEXTML native XML database with full-text search, metadata filtering, and complete version history for every content component. Search capabilities tie related content together across documents, helping teams maintain consistency across the regulated content library.
Time-to-Market Efficiency
DITA component reuse and structured workflows directly reduce time from authoring to publication. Document-level templates and baselined IFU templates let teams quickly create compliant content from proven starting points, whether drafting a new document or producing a variant of an existing one.
Life Sciences Documentation Solutions
Structured content management for regulatory-compliant IFUs, regulatory submissions, clinical documentation, and multilingual medical device content.
Get a DemoProduce regulatory-compliant Instructions for Use from structured DITA content. Component reuse means safety warnings, contraindications, and dosage instructions are authored once and managed through shared libraries, updating only the IFUs that require them. Configurable review and approval workflows enforce the review process regulators require.
Author structured documentation for medical devices, diagnostic instruments, and clinical software in an environment that also supports FDA 21 CFR Part 11 and EU MDR/IVDR workflows. Approval-tracking workflows record every reviewer and approver through status transitions.
Manage regulatory submission content and technical documentation with version-controlled DITA authoring. Dynamic Release Management handles documentation for different product variants and regulatory jurisdictions, and audit trails provide complete traceability for regulatory inspections.
Coordinate multilingual documentation delivery with Unified Localization. Topic-based translation workflows and TMS-agnostic automation support multiple translation vendor workflows, with MadTranslations integration ensuring translated content stays synchronized with source documents as products evolve and regulatory requirements change.
Supports the EU MDR/IVDR electronic IFU regulations expanding electronic Instructions for Use to all professionally-used medical devices. IXIA CCMS provides multi-format, multi-language publishing from a single DITA source for electronic delivery.
Maintain documentation that satisfies the ALCOA framework, Attributable, Legible, Contemporaneous, Original, and Accurate. IXIA CCMS audit trails, version control, and structured authoring enforce the data integrity practices that regulators expect under heightened global inspection scrutiny.
MadCap IXIA CCMS Resources
Videos & Tutorials
See MadCap IXIA CCMS in action. Watch tutorials covering DITA XML authoring, component content reuse, Dynamic Release Management, and multilingual publishing.
Watch Videos
Success Stories
Discover how enterprise teams use MadCap IXIA CCMS to manage regulated documentation with audit trails, approval workflows, and DITA component reuse at scale.
View Success Stories
IXIA CCMS Overview
MadCap IXIA CCMS is the enterprise-grade DITA component content management system for structured authoring, content reuse, and multilingual publishing at scale.
Learn MoreFrequently Asked Questions
MadCap IXIA CCMS supports FDA 21 CFR Part 11 compliance through electronic records, complete audit trails, and map-level approval workflows. Configurable review and approval workflows enforce the compliant status transitions required by regulatory environments.
Safety warnings, contraindications, drug interactions, and dosage instructions are authored as individual DITA components and reused across every IFU that references them. When a regulatory change affects shared content, you update it once and the CCMS monitors applicability, cascading changes only to the documents that require them.
Yes. The EU MDR/IVDR regulations expanding electronic Instructions for Use to all professionally-used medical devices require structured, multi-format, multi-language content management system. IXIA CCMS publishes from a single DITA source to multiple output formats and languages.
Life sciences customers include Biomerieux, Agfa, Siemens Healthineers, Brainlab, Intuitive Surgical, Roche Diagnostics, Biosense Webster, Baxter and Abbott.
DITA component reuse eliminates redundant authoring. Unified Localization sends only changed components to translators. Configurable review and approval workflows replace manual review cycles. Together, these capabilities directly reduce time from authoring to publication.
Streamline Regulated Documentation for Life Sciences
Get a personalized demo and see how MadCap IXIA CCMS helps life sciences teams produce regulatory-compliant, multilingual documentation with audit trails and approval workflows.
